Every article, presentation, spotlight, and news item we've tagged to Hallmarks of Aging.
Showing 25–48 of 225
Coordinated global demonstrations are pressuring governments to fund geroscience research and establish regulatory pathways that recognize aging as a treatable medical condition. The rallies highlight a critical gap between accelerating scientific advances in longevity research and stalled policy frameworks that remain anchored to disease-specific treatment models.
A new documentary translates geroscience research into accessible language for public audiences, emphasizing that lifestyle and environmental factors—not genetic destiny—are the primary drivers of aging outcomes. This shift from genetic determinism to behavioral agency represents a critical moment in moving longevity science from laboratory to practical application.
Cellular senescence plays a dual role in postpartum mammary gland remodeling—supporting normal tissue reorganization while simultaneously creating conditions that enhance tumor progression when oncogenic events coincide with gland involution. This mechanism reveals how a normally protective cellular state becomes pathogenic under specific developmental and genetic circumstances.
Researchers identified a hierarchical gene regulatory network controlling yeast lifespan, where peripheral genes act through master regulators that converge on functional modules governing stress response, autophagy, and proteostasis. This architecture provides a framework for dissecting genetic complexity in aging and maps directly to mechanisms that influence human longevity pathways.
Imaging mass cytometry analysis of breast tissue from 527 women reveals that aging is accompanied by decreased cellular density and proliferation, concurrent with increased proportions of inflammatory immune cells. These findings establish a cellular and spatial signature of breast aging that reflects broader patterns of tissue remodeling seen across the body.
Senescent macrophages expressing p21 and TREM2 accumulate with age and drive chronic inflammation and metabolic dysfunction in the liver. This identification of a specific senescent immune cell phenotype directly connects cellular aging to systemic metabolic decline and suggests a mechanistic target for interventions addressing age-related disease.
A pilot randomized controlled trial investigates whether reducing glycation stress—the accumulation of sugar-derived damage to proteins—can slow aging markers in postmenopausal women. Glycation is a hallmark of aging that accelerates decline across multiple physiological systems, making this intervention relevant to the practical toolkit of longevity medicine.
Blue light exposure triggers excessive mitochondrial fragmentation in retinal cells through a specific protein (Drp1), driving cellular changes associated with age-related macular degeneration. Blocking this fragmentation restores mitochondrial function and reverses the pathological transformation in both cell cultures and animal models.
Mitochondrial dysfunction is increasingly recognized as a central mechanism underlying age-related disease, not merely a feature of rare genetic conditions. The FDA approval of elamipretide (Forzinity) for Barth syndrome represents the first regulatory validation of mitochondria-targeted therapeutics, positioning this class of drugs as potential interventions for common age-related conditions including neurodegeneration and cardiac disease.
Tissue mechanical properties—specifically softness—regulate regenerative capacity in aging organisms. This finding reframes age-related decline not as inevitable cellular exhaustion but as a mechanical constraint that can be modulated, with direct implications for extending healthspan through structural optimization.
A single-cell chromatin atlas across 21 tissues reveals that aging involves coordinated, sex-specific regulatory remodeling rather than random molecular decay. The coordinated shifts across anatomically distinct organs suggest systemic drivers—circulating signals, immune tone, endocrine cues—offering both mechanistic insight and practical constraints for intervention design.
Clonal haematopoiesis reflects genomic instability with aging and links to malignancy, cardiovascular disease, and age-related conditions. Multiple forms of CH share common risk factors and may amplify inflammatory and immune dysfunction, offering insight into how cellular mutations drive aging-related pathology.
Microglia—brain immune cells—reorganize their internal structure with age in ways that correlate with functional decline. Subcellular transcript localization patterns reveal how these cells alter their morphology during aging, providing a cellular mechanism underlying age-related cognitive and neurological changes.
Host genetic capacity to manage oxidative stress determines whether microbiota interventions extend or shorten lifespan. Individuals with genetic variants affecting redox buffering show accelerated aging when exposed to the same microbial signals that promote longevity in genetically robust hosts. This finding establishes oxidative stress management as the critical variable in microbiome-driven aging outcomes.
Younger mice demonstrate faster wound healing due to a more robust senescent cell response, while the accumulation of senescent cells with age paradoxically impairs regeneration. This reveals a temporal window in which senescent cell activation supports tissue repair before becoming detrimental.
Aging muscle stem cells lose their capacity to use glutamine for lipid synthesis through reductive TCA cycling, a metabolic pathway essential for activation. Restoring this pathway represents a tractable intervention point against age-related muscle loss and functional decline.
Pharmacological reactivation of HIF-1α signaling in aged satellite cells restores lactate-driven epigenetic remodeling and shifts cells from senescence toward a regenerative state, with treated cells demonstrating enhanced myogenic capacity and increased ATP production. This identifies a metabolic-epigenetic axis relevant to age-related muscle decline and suggests a therapeutic target for sarcopenia.
Single-cell imaging of over 500 breast tissue samples reveals that aging is characterized by nonlinear loss of cellular density and a shift toward inflammatory composition. This finding identifies a specific tissue-level signature of aging that may serve as a marker for understanding how systemic aging progresses and potentially how to intervene.
Reduced insulin signaling extends lifespan in Drosophila, but the effect—beneficial or detrimental—depends on the genetic interaction between mitochondrial and nuclear DNA. This reveals that conserved aging mechanisms operate differently across individuals based on mito-nuclear epistasis, with direct implications for personalized longevity interventions.
Turquoise killifish demonstrate rapid, age-associated immune system deterioration marked by chronic inflammation, genomic instability, and functional decline. This model reveals how innate immune dysregulation accelerates aging trajectories in vertebrates, offering mechanistic insights applicable to understanding human immunosenescence.
p62 protein condensation drives clustering of damaged mitochondria during selective autophagy, acting as a quality control mechanism that slows mitochondrial turnover. ALS/FTD-associated mutations disrupt this clustering process, impairing the cell's ability to manage dysfunctional mitochondria—a hallmark of age-related neurodegeneration.
Oxidative damage biomarkers correlate with frailty in older women, providing measurable indicators of cellular stress that precede functional decline. Identifying these markers enables earlier intervention before frailty manifests clinically.
This research maps transcriptomic changes across multiple organs during aging in mice, revealing organ-specific and shared molecular signatures of senescence. Understanding these distinct aging patterns across tissues is fundamental to identifying intervention points for age-related decline.
ATP deficiency impairs dopamine packaging into synaptic vesicles by reducing function of VMAT2, a transporter that requires ATP energy, leading to dopamine oxidation and α-synuclein accumulation characteristic of Parkinson's disease. This mechanism links mitochondrial dysfunction to neurodegeneration in human dopaminergic neurons and may explain both familial and sporadic disease pathology.
